GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » Gross Margin %

MicroPort CardioFlow Medtech (HKSE:02160) Gross Margin % : 70.92% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. MicroPort CardioFlow Medtech's Gross Profit for the six months ended in Dec. 2023 was HK$123.9 Mil. MicroPort CardioFlow Medtech's Revenue for the six months ended in Dec. 2023 was HK$174.8 Mil. Therefore, MicroPort CardioFlow Medtech's Gross Margin % for the quarter that ended in Dec. 2023 was 70.92%.


The historical rank and industry rank for MicroPort CardioFlow Medtech's Gross Margin % or its related term are showing as below:

HKSE:02160' s Gross Margin % Range Over the Past 10 Years
Min: 29.31   Med: 59.11   Max: 68.39
Current: 68.39


During the past 6 years, the highest Gross Margin % of MicroPort CardioFlow Medtech was 68.39%. The lowest was 29.31%. And the median was 59.11%.

HKSE:02160's Gross Margin % is ranked better than
74.66% of 801 companies
in the Medical Devices & Instruments industry
Industry Median: 52.83 vs HKSE:02160: 68.39

MicroPort CardioFlow Medtech had a gross margin of 70.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for MicroPort CardioFlow Medtech was 0.00% per year.


MicroPort CardioFlow Medtech Gross Margin % Historical Data

The historical data trend for MicroPort CardioFlow Medtech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech Gross Margin % Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 29.31 43.66 59.11 64.59 68.39

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.11 63.67 65.50 66.10 70.92

Competitive Comparison of MicroPort CardioFlow Medtech's Gross Margin %

For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort CardioFlow Medtech's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where MicroPort CardioFlow Medtech's Gross Margin % falls into.



MicroPort CardioFlow Medtech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

MicroPort CardioFlow Medtech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=251.5 / 367.745
=(Revenue - Cost of Goods Sold) / Revenue
=(367.745 - 116.251) / 367.745
=68.39 %

MicroPort CardioFlow Medtech's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=123.9 / 174.756
=(Revenue - Cost of Goods Sold) / Revenue
=(174.756 - 50.822) / 174.756
=70.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MicroPort CardioFlow Medtech  (HKSE:02160) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MicroPort CardioFlow Medtech had a gross margin of 70.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


MicroPort CardioFlow Medtech Gross Margin % Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech (HKSE:02160) Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Microport Scientific Corporation 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech (HKSE:02160) Headlines

No Headlines